MediGene AG

200 articles with MediGene AG

• Medigene AG: Medigene appoints Axel-Sven Malkomes as CFO/CBDO

  2/11/2019

  Medigene AG announced that its Supervisory Board has appointed Axel-Sven Malkomes as Chief Financial Officer and Chief Business Development Officer effective 1 April 2019.

• Medigene AG: Medigene participates at four upcoming conferences

  1/17/2019

  Medigene AG announced its participation at the following upcoming investor and scientific conferences

• Medigene AG: Additional European patent granted for Medigene's DC vaccine platform

  1/8/2019

  Medigene AG reported today that an additional European Patent was granted for its dendritic cell (DC) vaccine platform.

• Medigene AG: Medigene Licenses Co-stimulator to Enhance TCR Therapies for Solid Tumors

  1/4/2019

  A mechanism expected to overcome checkpoint blockade in T cells

• Medigene AG: Medigene publishes topline interim data from ongoing Phase I/II clinical trial with DC vaccines in AML patients

  12/19/2018

  Topline-data from first half of treatment period (one year) 

• Medigene AG: Academic partner Oslo University Hospital presented clinical data on compassionate use of AML DC vaccine at ASH

  12/3/2018

  Medigene AG announced that researchers from Oslo University Hospital presented an update on clinical compassionate use (1) data of their dendritic cell (DC) vaccine utilizing Medigene's DC vaccine technology for production.

• Medigene AG: Medigene participates at further 2018 upcoming conferences

  11/27/2018

  Medigene AG today announced its participation at the following upcoming investor and scientific conferences

• Medigene reports financial & business results for the first nine months of 2018

  11/13/2018

  Medigene AG today reported financial results for the first 9 months of 2018 and provided a review of recent accomplishments and anticipated upcoming milestones.

• Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor

  11/13/2018

  TCR targeting HA-1 antigen for hematological and solid tumors provides initial clinical safety and tolerability data

• Medigene AG: Medigene participates at four conferences in November 2018

  11/1/2018

  Medigene AG today announced its participation at the following upcoming investor and scientific conferences:

• Medigene AG: Medigene participates at four conferences in October 2018

  10/2/2018

  Medigene AG today announced its participation at the following upcoming investor and scientific conferences:

• Medigene AG: Medigene participates at further conferences in September 2018

  9/12/2018

  Medigene AG today announced its participation at the following upcoming investor and scientific conferences:

• Medigene AG: Medigene announces inclusion in SDAX

  9/10/2018

  Medigene AG announces that the Medigene share will be part of the SDAX from 24 September 2018 onwards, following the restructuring of the Deutsche Börse indices.

• Medigene AG: Medigene announces change in executive leadership team

  9/7/2018

  Planegg announced today that the Chief Financial Officer (CFO), Dr. Thomas Taapken, will leave the Company for personal reasons and will resign from his CFO position effective August 31, 2018.

• Medigene AG: Medigene and Structured Immunity announce collaboration aimed at improving T Cell receptor development

  8/21/2018

  Structured Immunity, a biotechnology company specializing in the optimization and validation of T cell receptor (TCR) proteins and Medigene AG, a leading biotechnology company engaged in the development of immunotherapies for the treatment of cancer, today announced a research collaboration.

• Medigene AG: Medigene Reports Results for the First Half of 2018

  8/8/2018

  Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer, reports today on its business and financial results for the first half of 2018. In the first six months of 2018, Medigene significantly increased its revenue and reduced its loss. The company improves the financial guidance for the full year 2018.

• 

  Medigene and Bluebird Bio Expand Cancer Collaboration to $1.5 Billion

  5/14/2018

  Medigene and bluebird bio announced they are expanding a strategic research and development collaboration inked in September 2016.

• Medigene AG: 'Deutsche Krebshilfe Preis' Awarded to Professor Dolores Schendel

  2/5/2018

  From 1998 to 2013, Professor Schendel was Director of the Institute of Molecular Immunology at the Helmholtz Zentrum München.

• Medigene Strengthens its Patent Portfolio With a U.S. Patent on a Tagged TCR

  2/2/2018

  MediGene announces the grant of US patent 9,862,755 by the USPTO covering a high affinity T cell receptor with an epitope tag.

• Medigene Announces Participation at Six Upcoming Investor and Scientific Conferences

  1/19/2018

  MediGene today announced its participation at six upcoming investor and scientific conferences.